{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T01:41:09Z","timestamp":1777599669718,"version":"3.51.4"},"reference-count":28,"publisher":"American Society for Microbiology","issue":"9","license":[{"start":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T00:00:00Z","timestamp":1725408000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T00:00:00Z","timestamp":1725408000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100000060","name":"HHS | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"crossref","award":["R21AI114508"],"award-info":[{"award-number":["R21AI114508"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"crossref","award":["1I01BX001974"],"award-info":[{"award-number":["1I01BX001974"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"crossref","award":["1I01BX002872"],"award-info":[{"award-number":["1I01BX002872"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000060","name":"HHS | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"crossref","award":["UM1AI104681"],"award-info":[{"award-number":["UM1AI104681"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2024,9,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:sec>\n            <jats:title\/>\n            <jats:p>\n              Taniborbactam, a bicyclic boronate \u03b2-lactamase inhibitor with activity against\n              <jats:italic>Klebsiella pneumoniae<\/jats:italic>\n              carbapenemase (KPC), Verona integron\u2013encoded metallo-\u03b2-lactamase (VIM), New Delhi metallo-\u03b2-lactamase (NDM), extended-spectrum beta-lactamases (ESBLs), OXA-48, and AmpC \u03b2-lactamases, is under clinical development in combination with cefepime. Susceptibility of 200 previously characterized carbapenem-resistant\n              <jats:italic>K. pneumoniae<\/jats:italic>\n              and 197 multidrug-resistant (MDR)\n              <jats:italic>Pseudomonas aeruginosa<\/jats:italic>\n              to cefepime-taniborbactam and comparators was determined by broth microdilution. For\n              <jats:italic>K. pneumoniae<\/jats:italic>\n              (192 KPC; 7 OXA-48-related), MIC\n              <jats:sub>90<\/jats:sub>\n              values of \u03b2-lactam components for cefepime-taniborbactam, ceftazidime-avibactam, and meropenem-vaborbactam were 2, 2, and 1 mg\/L, respectively. For cefepime-taniborbactam, 100% and 99.5% of isolates of\n              <jats:italic>K. pneumoniae<\/jats:italic>\n              were inhibited at \u226416 mg\/L and \u22648 mg\/L, respectively, while 98.0% and 95.5% of isolates were susceptible to ceftazidime-avibactam and meropenem-vaborbactam, respectively. For\n              <jats:italic>P. aeruginosa<\/jats:italic>\n              , MIC\n              <jats:sub>90<\/jats:sub>\n              values of \u03b2-lactam components of cefepime-taniborbactam, ceftazidime-avibactam, ceftolozane-tazobactam, and meropenem-vaborbactam were 16, &gt;8, &gt;8, and &gt;4 mg\/L, respectively. Of 89 carbapenem-susceptible isolates, 100% were susceptible to ceftolozane-tazobactam, ceftazidime-avibactam, and cefepime-taniborbactam at \u22648 mg\/L. Of 73 carbapenem-intermediate\/resistant\n              <jats:italic>P. aeruginosa<\/jats:italic>\n              isolates without carbapenemases, 87.7% were susceptible to ceftolozane-tazobactam, 79.5% to ceftazidime-avibactam, and 95.9% and 83.6% to cefepime-taniborbactam at \u226416 mg\/L and \u22648 mg\/L, respectively. Cefepime-taniborbactam at \u226416 mg\/L and \u22648 mg\/L, respectively, was active against 73.3% and 46.7% of 15 VIM- and 60.0% and 35.0% of 20 KPC-producing\n              <jats:italic>P. aeruginosa<\/jats:italic>\n              isolates. Of all 108 carbapenem-intermediate\/resistant\n              <jats:italic>P. aeruginosa<\/jats:italic>\n              isolates, cefepime-taniborbactam was active against 86.1% and 69.4% at \u226416 mg\/L and \u22648 mg\/L, respectively, compared to 59.3% for ceftolozane-tazobactam and 63.0% for ceftazidime-avibactam. Cefepime-taniborbactam had\n              <jats:italic>in vitro<\/jats:italic>\n              activity comparable to ceftazidime-avibactam and greater than meropenem-vaborbactam against carbapenem-resistant\n              <jats:italic>K. pneumoniae<\/jats:italic>\n              and carbapenem-intermediate\/resistant MDR\n              <jats:italic>P. aeruginosa<\/jats:italic>\n              .\n            <\/jats:p>\n          <\/jats:sec>","DOI":"10.1128\/aac.00751-24","type":"journal-article","created":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T13:01:30Z","timestamp":1723467690000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":14,"title":["ARGONAUT-III and -V: susceptibility of carbapenem-resistant\n            <i>Klebsiella pneumoniae<\/i>\n            and multidrug-resistant\n            <i>Pseudomonas aeruginosa<\/i>\n            to the bicyclic boronate \u03b2-lactamase inhibitor taniborbactam combined with cefepime"],"prefix":"10.1128","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4235-7855","authenticated-orcid":true,"given":"Michael R.","family":"Jacobs","sequence":"first","affiliation":[{"name":"Case Western Reserve University, Cleveland, Ohio, USA"},{"name":"University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayman M.","family":"Abdelhamed","sequence":"additional","affiliation":[{"name":"University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caryn E.","family":"Good","sequence":"additional","affiliation":[{"name":"University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0131-7996","authenticated-orcid":true,"given":"Andrew R.","family":"Mack","sequence":"additional","affiliation":[{"name":"Department of Molecular Biology and Microbiology, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA"},{"name":"Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Research Service, Cleveland, Ohio, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher R.","family":"Bethel","sequence":"additional","affiliation":[{"name":"Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Research Service, Cleveland, Ohio, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Marshall","sequence":"additional","affiliation":[{"name":"Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Research Service, Cleveland, Ohio, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea M.","family":"Hujer","sequence":"additional","affiliation":[{"name":"Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Research Service, Cleveland, Ohio, USA"},{"name":"Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristine M.","family":"Hujer","sequence":"additional","affiliation":[{"name":"Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Research Service, Cleveland, Ohio, USA"},{"name":"Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6344-4141","authenticated-orcid":true,"given":"Robin","family":"Patel","sequence":"additional","affiliation":[{"name":"Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4784-3227","authenticated-orcid":true,"given":"David","family":"van Duin","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, University of North Carolina, Chapel Hill, North Carolina, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vance G.","family":"Fowler","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7636-5191","authenticated-orcid":true,"given":"Daniel D.","family":"Rhoads","sequence":"additional","affiliation":[{"name":"Case Western Reserve University, Cleveland, Ohio, USA"},{"name":"Department of Pathology, Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9013-1711","authenticated-orcid":false,"given":"David A.","family":"Six","sequence":"additional","affiliation":[{"name":"Venatorx Pharmaceuticals Inc., Malvern, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7827-7227","authenticated-orcid":true,"given":"Greg","family":"Moeck","sequence":"additional","affiliation":[{"name":"Venatorx Pharmaceuticals Inc., Malvern, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6994-4286","authenticated-orcid":false,"given":"Tsuyoshi","family":"Uehara","sequence":"additional","affiliation":[{"name":"Venatorx Pharmaceuticals Inc., Malvern, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9976-7898","authenticated-orcid":true,"given":"Krisztina M.","family":"Papp-Wallace","sequence":"additional","affiliation":[{"name":"Case Western Reserve University, Cleveland, Ohio, USA"},{"name":"Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Research Service, Cleveland, Ohio, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3299-894X","authenticated-orcid":true,"given":"Robert A.","family":"Bonomo","sequence":"additional","affiliation":[{"name":"Department of Molecular Biology and Microbiology, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA"},{"name":"Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Research Service, Cleveland, Ohio, USA"},{"name":"Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA"},{"name":"Departments of Biochemistry, Pharmacology, Proteomics and Bioinformatics, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA"},{"name":"CWRU-Cleveland VAMC Center for Antimicrobial Resistance and Epidemiology (Case VA CARES), Cleveland, Ohio, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","unstructured":"World Health Organization. 2022. 2021 antibacterial agents in clinical and preclinical development: an overview and analysis. Geneva: World Health Organization. Available from: https:\/\/www.who.int\/publications\/i\/item\/9789240047655"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2019.04.002"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa391"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01963-19"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.9b01518"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2304748"},{"key":"e_1_3_3_8_2","unstructured":"Venatorx Pharmaceuticals. 2023. Cefepime-taniborbactam vs meropenem in adults with VABP or ventilated HABP (CERTAIN-2). Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT06168734?id=NCT06168734&rank=1"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(19)30755-8"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00012-20"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01801-18"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy801"},{"key":"e_1_3_3_13_2","volume-title":"CLSI document M100-S30","author":"Clinical and Laboratory Standards Institute","year":"2020","unstructured":"Clinical and Laboratory Standards Institute. 2020. Performance standards for antimicrobial susceptibility testing; 30th informational supplement. In CLSI document M100-S30. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa373"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00145-19"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01053-21"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00253-22"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkab405"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1010334"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00115-20"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa053"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01676-21:AAC0167621"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02338-20"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01281-22"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-023-04697-4"},{"key":"e_1_3_3_26_2","unstructured":"Centers for Disease Control. 2024. Antimicrobial resistance & patient safety portal (AR&PSP) AR lab network data. Atlanta Georgia: U.S. Department of Health and Human Services CDC. Available from: https:\/\/arpsp.cdc.gov\/"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02636-14"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1080\/14756366.2017.1344235"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa345"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.00751-24","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.00751-24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T15:06:57Z","timestamp":1726672017000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/aac.00751-24"}},"subtitle":[],"editor":[{"given":"Alessandra","family":"Carattoli","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2024,9,4]]},"references-count":28,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9,4]]}},"alternative-id":["10.1128\/aac.00751-24"],"URL":"https:\/\/doi.org\/10.1128\/aac.00751-24","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,4]]},"assertion":[{"value":"2024-05-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00751-24"}}